SOURCE: TapImmune Inc.

September 10, 2007 09:30 ET

TapImmune Inc. Announces Initiation of Testing on Novel Cancer Vaccine

FDA Registered Facility Begins Testing on Company's Lead Product

VANCOUVER, BC--(Marketwire - September 10, 2007) - TapImmune Inc. (OTCBB: TPIM) (Frankfurt: GX1A), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA compliant testing company AppTec, headquartered in St. Paul, Minnesota, has begun preclinical testing of its lead product, a TAP-based therapeutic cancer vaccine. The immunotherapy vaccine is designed to treat a wide variety of TAP deficient carcinomas that include lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first step in the product development program that will bring the vaccine to Phase 1 Human studies.

After this initial testing and certification, TapImmune will move forward with the production of commercial grade vaccine in FDA approved facilities to commence toxicology and Phase I clinical trials.

The TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In pre-clinical animal models, the Company's vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system.

"This is a very promising technology that we believe could hold the key to making these types of cancers visible to our immune system thus allowing for an appropriate immune response," said Denis Corin CEO TapImmune Inc. "It's gratifying to see the progression from the lab to the development cycle."

The TAP molecule also works as an adjuvant or 'accelerant' to enhance targeted vaccines against infectious diseases. The company expects to develop products based on this application to ensure a deep product pipeline and broad market applicability for its technologies.

About TapImmune Inc.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the AdhTAP vaccine, restores and augments antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP-based vaccine adjuvant already proven to increase the efficacy of targeted prophylactic vaccines by up to 1000 times.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

Contact Information